CervoMed Inc. is set to present late-breaking data at the Clinical Trials on Alzheimer’s Disease Conference (CTAD) in Madrid, Spain, from October 29 to November 1, 2024, highlighting the potential of neflamapimod for treating dementia with Lewy bodies (DLB). The presentations will feature plasma biomarker data from the AscenD-LB Phase 2a study and baseline data from the ongoing RewinD-LB Phase 2b study.
John Alam, MD, CEO of CervoMed, expressed enthusiasm about the presentations, noting the urgent need for effective DLB treatments and the importance of the RewinD-LB study. The company anticipates reporting topline data from the RewinD-LB trial in December.
Biomarker Data and Clinical Activity
One presentation will focus on plasma biomarker data indicating that neflamapimod's clinical activity in DLB is mediated through effects on the basal forebrain cholinergic system. This system is critical for cognitive function and is significantly affected in DLB. The data suggests that neflamapimod may improve synaptic function by modulating this system.
RewinD-LB Trial Baseline Data
The second presentation will detail baseline data from participants enrolled in the RewinD-LB clinical trial. This large cohort of DLB patients shows no tau-related temporal lobe neurodegeneration, as defined by the absence of elevation in plasma ptau181. According to Dr. Alam, the baseline data confirms that the disease burden at study entry is consistent with the company's expectations when designing the study.
About Neflamapimod
Neflamapimod is an investigational, orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha (p38 MAPKα). CervoMed believes neflamapimod has the potential to treat synaptic dysfunction, a reversible aspect of neurodegenerative processes in DLB and other neurological disorders. The RewinD-LB trial is a Phase 2b study evaluating neflamapimod in patients with early-stage DLB.
